Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03950960 · ClinicalTrials.gov registry record · Phase 1
A Study to Investigate the Effects of Itraconazole on the Pharmacokinetics of BMS-986256 in Healthy Participants
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT03950960 is a Phase 1 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 15 participants.
The verdict
NCT03950960, a Phase 1 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the effect of cytochrome P450 3A4 inhibition by Itraconazole on the pharmacokinetics of BMS-986256.
Interventions
- DRUG Itraconazole
- DRUG BMS-986256
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2019-05-02 |
| Est. Completion | 2019-08-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03950960
The ClinicalTrials.gov registry entry for NCT03950960 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Itraconazole is the first listed.
NCT03950960 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03950960 about?
NCT03950960 is a clinical study titled "A Study to Investigate the Effects of Itraconazole on the Pharmacokinetics of BMS-986256 in Healthy Participants". The purpose of this study is to evaluate the effect of cytochrome P450 3A4 inhibition by Itraconazole on the pharmacokinetics of BMS-986256.
What is the current status of trial NCT03950960?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2019-05-02. Estimated completion is 2019-08-07.
What interventions are being tested in trial NCT03950960?
The interventions under investigation include: Itraconazole (DRUG), BMS-986256 (DRUG).
Who is sponsoring clinical trial NCT03950960?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.